DRTS
HOLD / NEUTRALMeanRevComposite
47.10
Technical
81.10
Fundamental
35.70
Rank
—
Price
14.77
Hurst
0.19
As of
Oct 5, 2026
Daily
Alpha Tau Medical Ltd.
HealthcareBiotechnologyAlpha Tau Medical Ltd. is an oncology company developing Alpha DaRT, a targeted radiation therapy approach designed to treat solid tumors. The technology is currently undergoing clinical testing across multiple cancer types including skin, oral, pancreatic, prostate, lung, liver, and breast cancers, with additional preclinical work ongoing. The company, based in Jerusalem, has also entered into a partnership focused specifically on advancing the therapy for prostate cancer treatment.
Market cap
$1.4B
P/E (trailing)
—
P/E (forward)
-27.85
PEG ratio
—
Dividend yield
0.00%
Beta
1.22
52w range
3.43 – 15.79
Return on equity
-141.68%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 14.67 (+247.6%) · range 3.47–15.50
Cycle position
58/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 9 · NOT READY · exit proximity 15
Conviction
21/ 100 · maturity 43%
VScore.2211
Buildup.2633
EMA entry setup.329
Fundamentals.1936
Volume profile
POC
9.83
Price vs POC
+49.3%
Overhead supply
12%
Runway
+1.2%
Value area 9.22–14.41 · 12% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.833 | Sep 15, 2026 |
| forum-chatter | 0.253 | Oct 6, 2026 |
Forward returns
Not yet labeled — the study prices these as positions mature.